Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems
Novo Nordisk is dealing with headwinds, but was its name really one of the big problems?
Overview
In some ways, Novo Nordisk (NYSE: NVO) clearly has an image problem. It effectively created the GLP-1 weight-loss drug market when it launched Wegovy. But it quickly lost the lead in this emerging niche to competitor Eli Lilly (NYSE: LLY). Now, Novo Nordisk has a chance to make a comeback as it launches a pill version of its GLP-1 drug. As it undertakes this effort, the company has chosen to rebrand, an odd decision at such a critical time. Here's what may be going on.
The key sentence in the company's announcement about its name change is this one: "As part of this, we will embrace the shorthand 'Novo' as our day-to-day name, while Novo Nordisk A/S remains our legal global company name." So the company isn't really changing its name; it is simply changing its branding.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.